Association of triple positivity with prognostic parameters and
overall survival in a population-based study of 6,122
HER2-positive breast cancer patients: analysis of real-world
clinical practice based on a research database

J 2020

Association of triple positivity with prognostic parameters and overall survival in a population-based study of 6,122 HER2-positive breast cancer patients: analysis of real-world clinical practice based on a research database

KOLAROVA, I.; J. VANASEK; M. DOLEZEL; J. STUK; A. HLAVKA et. al.

Základní údaje

Originální název

Association of triple positivity with prognostic parameters and overall survival in a population-based study of 6,122 HER2-positive breast cancer patients: analysis of real-world clinical practice based on a research database

Autoři

KOLAROVA, I. (203 Česká republika); J. VANASEK (203 Česká republika); M. DOLEZEL (203 Česká republika); J. STUK (203 Česká republika); A. HLAVKA (203 Česká republika); Ladislav DUŠEK (203 Česká republika, domácí); B. MELICHAR (203 Česká republika); T. BUCHLE (203 Česká republika); A. RYSKA (203 Česká republika); J. PRAUSOVA (203 Česká republika); K. PETRAKOVA (203 Česká republika); P. TESAROVA (203 Česká republika); J. PETERA (203 Česká republika); M. VOSMIK (203 Česká republika); K. HORACKOVA (203 Česká republika) a Jiří JARKOVSKÝ (203 Česká republika, garant, domácí)

Vydání

Neoplasma, Bratislava, Slovenská akademie vied, 2020, 0028-2685

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Slovensko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.575

Kód RIV

RIV/00216224:14110/20:00117599

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.4149/neo_2020_191023N1080

UT WoS

000600524900020

EID Scopus

2-s2.0-85095734063

Klíčová slova anglicky

breast cancer; triple positive; HER2-positive; hormone receptors; trastuzumab; overall survival

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 7. 1. 2021 08:21, Mgr. Tereza Miškechová

Anotace

V originále

Triple-positive breast cancer (TPBC), ie. HER2-positive (HER2+) and hormone receptors-positive breast cancer, is a specific subgroup of breast cancers. TPBC biology is characterized by strong mutual interactions between signaling pathways stimulated by estrogens and HER2 amplification. The present study aims to carry out a population-based analysis of treatment outcomes in a cohort of hormone receptor (HR) positive and negative breast cancer patients who were treated with anti-HER2 therapy in the Czech Republic. The BREAST research database was used as the data source for this retrospective analysis. he database covers approximately 95% of breast cancer patients treated with targeted therapies in the Czech Republic. The analysis included 6,122 HER2-positive patients. The patients were divided into two groups, based on estrogen receptor (ER) or progesterone receptor (PR) positivity: hormone receptor negative (HR-) patients had both ER- and PR-negative tumors (n-2,518), unlike positive (HR+) patients (n=3,604). HR+ patients were more often diagnosed premenopausal at the time of diagnosis, presented more often at stage I or II and their tumors were less commonly poorly differentiated. The overall survival (OS) was significantly higher in subgroups of HR+ patients according to treatment setting. When evaluated by stages, significantly higher OS was observed in HR+ patients diagnosed at stages II, III, and IV and regardless of tumor grade.

Citovat

KOLAROVA, I.; J. VANASEK; M. DOLEZEL; J. STUK; A. HLAVKA; Ladislav DUŠEK; B. MELICHAR; T. BUCHLE; A. RYSKA; J. PRAUSOVA; K. PETRAKOVA; P. TESAROVA; J. PETERA; M. VOSMIK; K. HORACKOVA a Jiří JARKOVSKÝ. Association of triple positivity with prognostic parameters and overall survival in a population-based study of 6,122 HER2-positive breast cancer patients: analysis of real-world clinical practice based on a research database. Neoplasma. Bratislava: Slovenská akademie vied, 2020, roč. 67, č. 6, s. 1373-1383. ISSN 0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo_2020_191023N1080.

@article{1721037,
   author = {Kolarova, I. and Vanasek, J. and Dolezel, M. and Stuk, J. and Hlavka, A. and Dušek, Ladislav and Melichar, B. and Buchle, T. and Ryska, A. and Prausova, J. and Petrakova, K. and Tesarova, P. and Petera, J. and Vosmik, M. and Horackova, K. and Jarkovský, Jiří},
   article_location = {Bratislava},
   article_number = {6},
   doi = {http://dx.doi.org/10.4149/neo_2020_191023N1080},
   keywords = {breast cancer; triple positive; HER2-positive; hormone receptors; trastuzumab; overall survival},
   language = {eng},
   issn = {0028-2685},
   journal = {Neoplasma},
   title = {Association of triple positivity with prognostic parameters and overall survival in a population-based study of 6,122 HER2-positive breast cancer patients: analysis of real-world clinical practice based on a research database},
   url = {http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=6782&category_id=85&option=com_virtuemart},
   volume = {67},
   year = {2020}
}

TY  - JOUR
ID  - 1721037
AU  - Kolarova, I. - Vanasek, J. - Dolezel, M. - Stuk, J. - Hlavka, A. - Dušek, Ladislav - Melichar, B. - Buchle, T. - Ryska, A. - Prausova, J. - Petrakova, K. - Tesarova, P. - Petera, J. - Vosmik, M. - Horackova, K. - Jarkovský, Jiří
PY  - 2020
TI  - Association of triple positivity with prognostic parameters and overall survival in a population-based study of 6,122 HER2-positive breast cancer patients: analysis of real-world clinical practice based on a research database
JF  - Neoplasma
VL  - 67
IS  - 6
SP  - 1373-1383
EP  - 1373-1383
PB  - Slovenská akademie vied
SN  - 00282685
KW  - breast cancer
KW  - triple positive
KW  - HER2-positive
KW  - hormone receptors
KW  - trastuzumab
KW  - overall survival
UR  - http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=6782&category_id=85&option=com_virtuemart
L2  - http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=6782&category_id=85&option=com_virtuemart
N2  - Triple-positive breast cancer (TPBC), ie. HER2-positive (HER2+) and hormone receptors-positive breast cancer, is a specific subgroup of breast cancers. TPBC biology is characterized by strong mutual interactions between signaling pathways stimulated by estrogens and HER2 amplification. The present study aims to carry out a population-based analysis of treatment outcomes in a cohort of hormone receptor (HR) positive and negative breast cancer patients who were treated with anti-HER2 therapy in the Czech Republic. The BREAST research database was used as the data source for this retrospective analysis. he database covers approximately 95% of breast cancer patients treated with targeted therapies in the Czech Republic. The analysis included 6,122 HER2-positive patients. The patients were divided into two groups, based on estrogen receptor (ER) or progesterone receptor (PR) positivity: hormone receptor negative (HR-) patients had both ER- and PR-negative tumors (n-2,518), unlike positive (HR+) patients (n=3,604). HR+ patients were more often diagnosed premenopausal at the time of diagnosis, presented more often at stage I or II and their tumors were less commonly poorly differentiated. The overall survival (OS) was significantly higher in subgroups of HR+ patients according to treatment setting. When evaluated by stages, significantly higher OS was observed in HR+ patients diagnosed at stages II, III, and IV and regardless of tumor grade.
ER  -

KOLAROVA, I.; J. VANASEK; M. DOLEZEL; J. STUK; A. HLAVKA; Ladislav DUŠEK; B. MELICHAR; T. BUCHLE; A. RYSKA; J. PRAUSOVA; K. PETRAKOVA; P. TESAROVA; J. PETERA; M. VOSMIK; K. HORACKOVA a Jiří JARKOVSKÝ. Association of triple positivity with prognostic parameters and overall survival in a population-based study of 6,122 HER2-positive breast cancer patients: analysis of real-world clinical practice based on a research database. \textit{Neoplasma}. Bratislava: Slovenská akademie vied, 2020, roč.~67, č.~6, s.~1373-1383. ISSN~0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo\_{}2020\_{}191023N1080.

Přehled o publikaci